RNLX vs. LPSN, PODC, IZEA, QMCO, INUV, ENCP, AWRE, IRIX, KTCC, and NSYS
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include LivePerson (LPSN), PodcastOne (PODC), IZEA Worldwide (IZEA), Quantum (QMCO), Inuvo (INUV), Energem (ENCP), Aware (AWRE), IRIDEX (IRIX), Key Tronic (KTCC), and Nortech Systems (NSYS). These companies are all part of the "computer and technology" sector.
LivePerson (NASDAQ:LPSN) and Renalytix (NASDAQ:RNLX) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
LivePerson has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Renalytix has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500.
In the previous week, LivePerson had 2 more articles in the media than Renalytix. MarketBeat recorded 2 mentions for LivePerson and 0 mentions for Renalytix. Renalytix's average media sentiment score of 0.25 beat LivePerson's score of 0.00 indicating that LivePerson is being referred to more favorably in the media.
LivePerson received 471 more outperform votes than Renalytix when rated by MarketBeat users. Likewise, 58.56% of users gave LivePerson an outperform vote while only 32.00% of users gave Renalytix an outperform vote.
79.8% of LivePerson shares are owned by institutional investors. Comparatively, 9.9% of Renalytix shares are owned by institutional investors. 2.0% of LivePerson shares are owned by insiders. Comparatively, 17.8% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
LivePerson presently has a consensus price target of $2.58, indicating a potential upside of 336.60%. Renalytix has a consensus price target of $5.00, indicating a potential upside of 623.07%. Given LivePerson's stronger consensus rating and higher probable upside, analysts plainly believe Renalytix is more favorable than LivePerson.
LivePerson has a net margin of -24.99% compared to LivePerson's net margin of -1,736.47%. Renalytix's return on equity of -47.71% beat LivePerson's return on equity.
Renalytix has lower revenue, but higher earnings than LivePerson. Renalytix is trading at a lower price-to-earnings ratio than LivePerson, indicating that it is currently the more affordable of the two stocks.
Summary
LivePerson beats Renalytix on 10 of the 17 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
